Type

Range

Units

Status

Start Date

End Date

Financing

Study Design

Brief description/objective

Patients with locally advanced oesophageal cancer are evaluable for a participation in this trial. The standard treatment for these patients is neoadjuvant chemoradia-tion followed by surgery. Patients receiving a complete pathological remission after neoadjuvant therapy have a 5y-survival of 75-80% (Swiss data), patients with macro-scopic tumor left do much worse with a 5y survival rate of only about 40%. The direct oesophagectomy is the international standard however, it has itself a relevant long-term morbidity and a mortality of 5-10%. Therefore, it exists a chronic controversy whether patients with good response after neoadjuvant therapy should still be operated or not, assuming this operation is without rele-vant impact on survival but increases the morbidity and mortality only.